Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China flag China · Delayed Price · Currency is CNY
27.22
-0.30 (-1.09%)
Nov 17, 2026, 3:00 PM CST

SHA:688076 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
941.12913.79571.39749.08399.96591.88
Trading Asset Securities
214116208-43.0187.13
Cash & Short-Term Investments
1,1551,030779.39749.08442.98679.01
Cash Growth
6.86%32.13%4.05%69.10%-34.76%353.54%
Accounts Receivable
537.73508.32539.21297.26251.29143.37
Other Receivables
14.1774.9963.293.271.191.05
Receivables
551.9583.31602.5300.53252.48144.41
Inventory
949.97859.52584.04377.17323.48250.82
Prepaid Expenses
-0.09----
Other Current Assets
113.2339.6739.667.9833.5329.86
Total Current Assets
2,7702,5122,0061,4951,0521,104
Property, Plant & Equipment
3,1352,9921,8921,405988.47706.55
Long-Term Investments
270.59234.47215.04117.594.5-
Goodwill
156.34156.34156.34156.34156.34160.92
Other Intangible Assets
198.84154.82108.19112.198.1888.57
Long-Term Deferred Tax Assets
155.92128.2184.3746.6528.1316.63
Long-Term Deferred Charges
377.98347.59203.241.0338.7715.66
Other Long-Term Assets
121.21214.69409.4173.8465.4434.46
Total Assets
7,1866,7405,0743,5472,5222,127

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
599.37319.92159.7141.9387.6172.36
Accrued Expenses
77.34179.66149.1286.1448.4943.99
Short-Term Debt
819.061,0171,044546.02318.7377.27
Current Portion of Long-Term Debt
735.15276.1117.8940.08--
Current Portion of Leases
-15.39.795.291.473.64
Current Income Taxes Payable
29.696.0619.3511.475.37-
Current Unearned Revenue
76.8648.1761.218.396.8526.17
Other Current Liabilities
25.01300.84191.83134.0182.851.96
Total Current Liabilities
2,3622,1631,753973.34551.32275.4
Long-Term Debt
1,2261,322445.21286.49--
Long-Term Leases
26.4628.8925.7517.18-2.74
Long-Term Unearned Revenue
161.04156.855.9931.4635.3221.74
Long-Term Deferred Tax Liabilities
8.28.278.6110.1610.774.26
Other Long-Term Liabilities
17659.18107.4339.31-14
Total Liabilities
3,9603,7392,3961,358597.41318.14

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
316.82316.05219.78213.18213.18213.18
Additional Paid-In Capital
1,7621,7551,5981,3411,3191,318
Retained Earnings
1,144919.08766.56495.37374.95277.82
Comprehensive Income & Other
-4.09-4.3672.17120.233.332.2
Total Common Equity
3,2192,9862,6562,1701,9101,811
Minority Interest
7.6716.221.9519.0414.66-2.61
Shareholders' Equity
3,2263,0022,6782,1891,9251,809
Total Liabilities & Equity
7,1866,7405,0743,5472,5222,127

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,8062,6601,642895.07320.1983.65
Net Cash (Debt)
-1,651-1,630-863.06-145.98122.79595.36
Net Cash Growth
-----79.38%-
Net Cash Per Share
-5.23-5.20-2.80-0.490.412.21
Filing Date Shares Outstanding
316.82316.05307.69298.46298.46298.46
Total Common Shares Outstanding
316.82316.05307.69298.46298.46298.46
Working Capital
407.76349.12252.82521.43501.15828.71
Book Value Per Share
10.169.458.637.276.406.07
Tangible Book Value
2,8632,6742,3921,9021,6561,562
Tangible Book Value Per Share
9.048.467.776.375.555.23
Buildings
---504.29476.24376.08
Machinery
-2,4181,6031,123652.13529
Construction In Progress
-692.57339.92185.96180.1134.85